377 related articles for article (PubMed ID: 12071785)
1. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.
Shakir SA; Layton D
Drug Saf; 2002; 25(6):467-71. PubMed ID: 12071785
[TBL] [Abstract][Full Text] [Related]
2. Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance.
Perrio M; Voss S; Shakir SA
Drug Saf; 2007; 30(4):333-46. PubMed ID: 17408310
[TBL] [Abstract][Full Text] [Related]
3. Considerations on causality in pharmacovigilance.
Edwards IR
Int J Risk Saf Med; 2012; 24(1):41-54. PubMed ID: 22436259
[TBL] [Abstract][Full Text] [Related]
4. The Bradford Hill criteria and zinc-induced anosmia: a causality analysis.
Davidson TM; Smith WM
Arch Otolaryngol Head Neck Surg; 2010 Jul; 136(7):673-6. PubMed ID: 20644061
[TBL] [Abstract][Full Text] [Related]
5. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
Goldman SA
Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
[No Abstract] [Full Text] [Related]
6. Good pharmacovigilance practices: technology enabled.
Nelson RC; Palsulich B; Gogolak V
Drug Saf; 2002; 25(6):407-14. PubMed ID: 12071777
[TBL] [Abstract][Full Text] [Related]
7. Idiopathic environmental intolerance: Part 1: A causation analysis applying Bradford Hill's criteria to the toxicogenic theory.
Staudenmayer H; Binkley KE; Leznoff A; Phillips S
Toxicol Rev; 2003; 22(4):235-46. PubMed ID: 15189046
[TBL] [Abstract][Full Text] [Related]
8. An updated method improved the assessment of adverse drug reaction in routine pharmacovigilance.
Théophile H; André M; Arimone Y; Haramburu F; Miremont-Salamé G; Bégaud B
J Clin Epidemiol; 2012 Oct; 65(10):1069-77. PubMed ID: 22910538
[TBL] [Abstract][Full Text] [Related]
9. [The French pharmacovigilance system: structure and missions].
Welsch M; Alt M; Richard MH; Imbs JL
Presse Med; 2000 Jan; 29(2):102-6. PubMed ID: 10682040
[TBL] [Abstract][Full Text] [Related]
10. Applying the Bradford Hill Criteria for Causation to Repetitive Head Impacts and Chronic Traumatic Encephalopathy.
Nowinski CJ; Bureau SC; Buckland ME; Curtis MA; Daneshvar DH; Faull RLM; Grinberg LT; Hill-Yardin EL; Murray HC; Pearce AJ; Suter CM; White AJ; Finkel AM; Cantu RC
Front Neurol; 2022; 13():938163. PubMed ID: 35937061
[TBL] [Abstract][Full Text] [Related]
11. Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity.
Maro JC; Brown JS; Dal Pan GJ; Kulldorff M
Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):839-48. PubMed ID: 24700557
[TBL] [Abstract][Full Text] [Related]
12. European commission consultation on pharmacovigilance.
Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
[No Abstract] [Full Text] [Related]
13. Pharmacoepidemiology and its input to pharmacovigilance.
Faillie JL; Montastruc F; Montastruc JL; Pariente A
Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
[TBL] [Abstract][Full Text] [Related]
14. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
[TBL] [Abstract][Full Text] [Related]
15. The Erice Manifesto: for global reform of the safety of medicines in patient care.
Drug Saf; 2007; 30(3):187-90. PubMed ID: 17343426
[TBL] [Abstract][Full Text] [Related]
16. A supervised adverse drug reaction signalling framework imitating Bradford Hill's causality considerations.
Reps JM; Garibaldi JM; Aickelin U; Gibson JE; Hubbard RB
J Biomed Inform; 2015 Aug; 56():356-68. PubMed ID: 26116429
[TBL] [Abstract][Full Text] [Related]
17. What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research.
Madigan D; Ryan P
Epidemiology; 2011 Sep; 22(5):629-31. PubMed ID: 21811110
[No Abstract] [Full Text] [Related]
18. Monitoring medicines use: the role of the clinical pharmacologist.
Williams D
Br J Clin Pharmacol; 2012 Oct; 74(4):685-90. PubMed ID: 22554404
[TBL] [Abstract][Full Text] [Related]
19. From pharmacovigilance to pharmacoperformance.
Peachey J
Drug Saf; 2002; 25(6):399-405. PubMed ID: 12071776
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of drugs safety signals that predict safety related product information update.
Insani WN; Pacurariu AC; Mantel-Teeuwisse AK; Gross-Martirosyan L
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):789-796. PubMed ID: 29797381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
